Pharsight

1. List of Balversa drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8895601	JANSSEN BIOTECH	Pyrazolyl quinoxaline kinase inhibitors	May, 2031 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9464071	JANSSEN BIOTECH	Pyrazolyl quinoxaline kinase inhibitors	Apr, 2031 (7 years from now)
US9902714	JANSSEN BIOTECH	Quinoxaline derivatives useful as FGFR kinase modulators	Mar, 2035 (11 years from now)
US10898482	JANSSEN BIOTECH	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	Feb, 2036 (12 years from now)
US11077106	JANSSEN BIOTECH	Cancer treatment	Feb, 2038 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: 2023-04-13

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemot...

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

BALVERSA family patents

United States

European Union

Singapore

China

Australia

Israel

Poland

Slovenia

Korea, Republic of

Taiwan

Lithuania

Japan

Denmark

Croatia

Hungary

Spain

Mexico

Portugal

Jordan

Canada

Ukraine

Costa Rica

Morocco

Chile

Philippines

Brazil

Argentina

Nicaragua

United Kingdom

New Zealand

South Africa

Cyprus

Hong Kong

Turkey

India

Malaysia

Colombia

Ecuador

^new

2. List of Erleada drug patents

Application	Filing Date	Opposition Party	Legal Status
EP19169275A	2022-02-04	Generics [UK] Limited	Granted and Under Opposition
EP17187458A	2021-06-02	Sandoz AG	Granted and Under Opposition
EP17187458A	2021-06-02	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP17187458A	2021-06-02	Synthon BV	Granted and Under Opposition
EP18157435A	2021-04-08	SANDOZ AG	Granted and Under Opposition
EP18157435A	2021-04-08	Sagittarius Intellectual Property Consultants Ltd	Granted and Under Opposition
EP13800681A	2019-01-18	Sagittarius Intellectual Property LLP	Granted and Under Opposition
EP13800681A	2019-01-18	Generics (U.K.) Limited	Granted and Under Opposition
EP13800681A	2019-01-18	Luigi, Rumi	Granted and Under Opposition

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159	JANSSEN BIOTECH	Substituted diazaspiroalkanes as androgen receptor modulators	Mar, 2027 (3 years from now)
US8445507	JANSSEN BIOTECH	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Sep, 2030 (7 years from now)
US9481663	JANSSEN BIOTECH	Crystalline forms of an androgen receptor modulator	Jun, 2033 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261	JANSSEN BIOTECH	Substituted diazaspiroalkanes as androgen receptor modulators	Mar, 2027 (3 years from now)
US8802689	JANSSEN BIOTECH	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases	Mar, 2027 (3 years from now)
USRE49353	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US10052314	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US9884054	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US10849888	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US10702508	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer	Apr, 2038 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 2022-02-14

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with a gnrh agonist of non-m...

Dosage: TABLET;ORAL